Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 5

Comparison of adverse events between our study and previous clinical studies of intrathecal autologous MSCs.

Adverse events (person-time)	Total (%)	Our study (%)	Literature review (%)
Headache	76 (6.47)	3 (2.05)	73 (7.10)	0.032
Dizziness	2 (0.17)	2 (1.37)	0 (0.00)	0.015
Fever	86 (7.32)	5 (3.42)	81 (7.88)	0.053
Nausea	12 (1.02)	2 (1.37)	10 (0.97)	0.995
Pain at puncture site	81 (6.90)	6 (4.11)	75 (7.30)	0.155
Neck pain	3 (0.26)	1 (0.68)	2 (0.19)	0.824